Dual Perspectives on DAPT
Baroreflex activation therapy may benefit HF patients without CRT
Lipid Forum II Highlights
Case Study: Elderly Woman with Type 2 Diabetes Mellitus and Acute Coronary Syndrome
Edwards Lifesciences announced that it has implemented a temporary pause in enrollment in its Fortis clinical program for development of a transcatheter mitral valve replacement system.
“We observed evidence of valve thrombosis that we believe warrants additional investigation,” the company stated in a press release. “We are working closely with the trial investigators and heart teams to gather additional information in this early study of transcatheter mitral valve replacement therapy.”
This activity is supported by an educational grant from Daiichi Sankyo, Inc. and Lilly USA, LLC
No commercial support for this activity.
CVD prevention, treatment challenging as patients with HIV and HCV live longer
A tribute to Elijah Saunders, MD
A look at coagulation assays for target-specific oral anticoagulants
This feature offers timely executive summaries of the most relevant journals in cardiology.
Snapshot summaries of recent study results in cardiology.
Your central portal for information presented at ACC 2015.
Your resource for news and videos from SCAI 2014.
This exclusive Healio resource provides you a comprehensive window into what your colleagues and key opinion leaders are saying about current and future drugs and devices and their impact on patient outcomes.
Related story »
View past polls »
Search Healio's robust listing of national and international medical meetings.
©2015 All Rights Reserved.